APD 916

Drug Profile

APD 916

Alternative Names: APD916

Latest Information Update: 18 Jul 2011

Price : $50

At a glance

  • Originator Arena Pharmaceuticals
  • Class
  • Mechanism of Action Histamine H3 receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Cataplexy; Narcolepsy

Most Recent Events

  • 13 Jul 2011 Suspended - Phase-I for Narcolepsy in USA (PO)
  • 13 Jul 2011 Suspended - Phase-I for Cataplexy in USA (PO)
  • 21 Oct 2010 Adverse events and pharmacokinetics data from a phase I trial in volunteers released by Arena Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top